VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Advances in allogeneic CAR-T therapy in lymphoma

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses advances in allogeneic CAR-T therapy for the treatment of relapsed/refractory (R/R) lymphoma. Dr Lin first highlights the challenges surrounding the use of autologous CAR-T therapy, and then goes on to discuss the excitement surrounding the use of allogeneic products. To conclude, Dr Lin comments on the importance of further investigating the safety and efficacy of allogeneic CAR-Ts, and the promise of these agents for the future treatment of R/R disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter